Active and inactive L-prolyl-L-leucyl glycinamide synthetic analogs in rat models of levodopa-treated Parkinson's disease

Todd C. Case; Stuart R. Snider; Victor J. Hruby; Todd Rockway

doi:10.1016/0024-3205(85)90150-X

Active and inactive L-prolyl-L-leucyl glycinamide synthetic analogs in rat models of levodopa-treated Parkinson's disease

Todd C. Case, Stuart R. Snider, Victor J. Hruby, Todd Rockway

Chemistry and Biochemistry

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

The tripeptide, L-prolyl-L-leucyl-glycinamide (PLG) has been shown to facilitate dopaminergic mechanisms in the brain. In the present study, we evaluated the interaction of PLG and its synthetic analogs with levodopa in two animal models of Parkinson's disease. In one experiment using rats with chronic unilateral lesions of the nigrostriatal dopamine pathway, PLG and Z-PLG potentiated the contraversive rotation elicited by levodopa with carbidopa (L/C). In a second experiment using reserpinized rats, PLG, Z-PLG and cyclo-LG potentiated L/C reversal of hypokinesia. Further studies of the PLG analogs, Z-PLG and cyclo-LG as adjunctive drugs with levodopa in the treatment of parkinsonism are warranted.

Original language	English (US)
Pages (from-to)	2531-2537
Number of pages	7
Journal	Life Sciences
Volume	36
Issue number	26
DOIs	https://doi.org/10.1016/0024-3205(85)90150-X
State	Published - Jul 1 1985

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)
Pharmacology, Toxicology and Pharmaceutics(all)

Access to Document

10.1016/0024-3205(85)90150-X

Cite this

@article{55cea96663ef40b5928df27b52f6bd12,

title = "Active and inactive L-prolyl-L-leucyl glycinamide synthetic analogs in rat models of levodopa-treated Parkinson's disease",

abstract = "The tripeptide, L-prolyl-L-leucyl-glycinamide (PLG) has been shown to facilitate dopaminergic mechanisms in the brain. In the present study, we evaluated the interaction of PLG and its synthetic analogs with levodopa in two animal models of Parkinson's disease. In one experiment using rats with chronic unilateral lesions of the nigrostriatal dopamine pathway, PLG and Z-PLG potentiated the contraversive rotation elicited by levodopa with carbidopa (L/C). In a second experiment using reserpinized rats, PLG, Z-PLG and cyclo-LG potentiated L/C reversal of hypokinesia. Further studies of the PLG analogs, Z-PLG and cyclo-LG as adjunctive drugs with levodopa in the treatment of parkinsonism are warranted.",

author = "Case, {Todd C.} and Snider, {Stuart R.} and Hruby, {Victor J.} and Todd Rockway",

note = "Funding Information: When given intravenously to parkinsonism patients receiving levodopa, PLG improved clinical symptoms (7). This observation was followed by a study on oral administration (8) and by attempts at confirmation by other groups (9-11). Later studies (lid not. show consistent results, possibly because of the rapid *T.C.C. and S.R.S. supported by the Parkinson's Disease Foundation, U.S.P.H.S. Grant T35HL07479, and the Gen-Mort Robbins Foundation, and V.J.H. and T.R. by U.S.P.H.S. Grant AM17420. ** To whom reprint requests should be addressed.",

year = "1985",

month = jul,

day = "1",

doi = "10.1016/0024-3205(85)90150-X",

language = "English (US)",

volume = "36",

pages = "2531--2537",

journal = "Life Sciences",

issn = "0024-3205",

publisher = "Elsevier Inc.",

number = "26",

}

TY - JOUR

T1 - Active and inactive L-prolyl-L-leucyl glycinamide synthetic analogs in rat models of levodopa-treated Parkinson's disease

AU - Case, Todd C.

AU - Snider, Stuart R.

AU - Hruby, Victor J.

AU - Rockway, Todd

N1 - Funding Information: When given intravenously to parkinsonism patients receiving levodopa, PLG improved clinical symptoms (7). This observation was followed by a study on oral administration (8) and by attempts at confirmation by other groups (9-11). Later studies (lid not. show consistent results, possibly because of the rapid *T.C.C. and S.R.S. supported by the Parkinson's Disease Foundation, U.S.P.H.S. Grant T35HL07479, and the Gen-Mort Robbins Foundation, and V.J.H. and T.R. by U.S.P.H.S. Grant AM17420. ** To whom reprint requests should be addressed.

PY - 1985/7/1

Y1 - 1985/7/1

N2 - The tripeptide, L-prolyl-L-leucyl-glycinamide (PLG) has been shown to facilitate dopaminergic mechanisms in the brain. In the present study, we evaluated the interaction of PLG and its synthetic analogs with levodopa in two animal models of Parkinson's disease. In one experiment using rats with chronic unilateral lesions of the nigrostriatal dopamine pathway, PLG and Z-PLG potentiated the contraversive rotation elicited by levodopa with carbidopa (L/C). In a second experiment using reserpinized rats, PLG, Z-PLG and cyclo-LG potentiated L/C reversal of hypokinesia. Further studies of the PLG analogs, Z-PLG and cyclo-LG as adjunctive drugs with levodopa in the treatment of parkinsonism are warranted.

AB - The tripeptide, L-prolyl-L-leucyl-glycinamide (PLG) has been shown to facilitate dopaminergic mechanisms in the brain. In the present study, we evaluated the interaction of PLG and its synthetic analogs with levodopa in two animal models of Parkinson's disease. In one experiment using rats with chronic unilateral lesions of the nigrostriatal dopamine pathway, PLG and Z-PLG potentiated the contraversive rotation elicited by levodopa with carbidopa (L/C). In a second experiment using reserpinized rats, PLG, Z-PLG and cyclo-LG potentiated L/C reversal of hypokinesia. Further studies of the PLG analogs, Z-PLG and cyclo-LG as adjunctive drugs with levodopa in the treatment of parkinsonism are warranted.

UR - http://www.scopus.com/inward/record.url?scp=0021799812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021799812&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(85)90150-X

DO - 10.1016/0024-3205(85)90150-X

M3 - Article

C2 - 2861549

AN - SCOPUS:0021799812

SN - 0024-3205

VL - 36

SP - 2531

EP - 2537

JO - Life Sciences

JF - Life Sciences

IS - 26

ER -

Active and inactive L-prolyl-L-leucyl glycinamide synthetic analogs in rat models of levodopa-treated Parkinson's disease

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this